ATE232394T1 - Verwendung von modifiziertem c-reaktiven protein zur herstellung eines medikaments zur behandlung von krebs - Google Patents

Verwendung von modifiziertem c-reaktiven protein zur herstellung eines medikaments zur behandlung von krebs

Info

Publication number
ATE232394T1
ATE232394T1 AT93910710T AT93910710T ATE232394T1 AT E232394 T1 ATE232394 T1 AT E232394T1 AT 93910710 T AT93910710 T AT 93910710T AT 93910710 T AT93910710 T AT 93910710T AT E232394 T1 ATE232394 T1 AT E232394T1
Authority
AT
Austria
Prior art keywords
mammal
mcrp
modified
cancer
reactive protein
Prior art date
Application number
AT93910710T
Other languages
English (en)
Inventor
Lawrence A Potempa
John J Kresl
Byron E Anderson
Original Assignee
Immtech Internat Inc
Univ Northwestern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immtech Internat Inc, Univ Northwestern filed Critical Immtech Internat Inc
Application granted granted Critical
Publication of ATE232394T1 publication Critical patent/ATE232394T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/968—High energy substrates, e.g. fluorescent, chemiluminescent, radioactive
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/804—Radioisotope, e.g. radioimmunoassay
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT93910710T 1992-04-24 1993-04-22 Verwendung von modifiziertem c-reaktiven protein zur herstellung eines medikaments zur behandlung von krebs ATE232394T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/874,263 US5283238A (en) 1992-04-24 1992-04-24 Methods of treating cancer using modified C-reactive protein
PCT/US1993/003769 WO1993021944A1 (en) 1992-04-24 1993-04-22 Methods of treating cancer using modified c-reactive protein

Publications (1)

Publication Number Publication Date
ATE232394T1 true ATE232394T1 (de) 2003-02-15

Family

ID=25363358

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93910710T ATE232394T1 (de) 1992-04-24 1993-04-22 Verwendung von modifiziertem c-reaktiven protein zur herstellung eines medikaments zur behandlung von krebs

Country Status (8)

Country Link
US (2) US5283238A (de)
EP (1) EP0637246B1 (de)
JP (2) JPH07505905A (de)
AT (1) ATE232394T1 (de)
AU (1) AU668168B2 (de)
CA (1) CA2132001C (de)
DE (1) DE69332688T2 (de)
WO (1) WO1993021944A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5593897A (en) * 1988-04-04 1997-01-14 Northwestern University Binding of immune complexes by modified forms of C-reactive protein
US5405832A (en) * 1991-11-27 1995-04-11 Immtech International Inc. Method of treating non-streptococcal bacterial infections
US5874238A (en) * 1993-02-26 1999-02-23 Immtech International Inc. Mutant protein and methods and materials for making and using it
WO1993010799A1 (en) * 1991-11-27 1993-06-10 Immtech International Incorporated Method of treating viral infections
US6703219B1 (en) 1993-02-26 2004-03-09 Immtech International Inc. Mutant protein and methods and materials for making and using it
US5547931A (en) * 1994-02-23 1996-08-20 Immtech International Inc. Methods of stimulatory thrombocytopoiesis using modified C-reactive protein
US6331403B1 (en) 1998-08-19 2001-12-18 Lawrence A. Potempa Use of mCRP to slow cell growth and to promote maturation of cells
AU6130299A (en) * 1998-08-19 2000-03-14 Immtech International, Inc. Use of mcrp for delivery of materials into cells
US6190670B1 (en) * 1999-04-12 2001-02-20 Immtech International Inc. Use of mCRP to enhance immune responses
US7115665B1 (en) 2000-11-16 2006-10-03 Onocozyme Pharma, Inc. Inhibitors of endo-exonuclease activity for treating cancer
DK1231910T3 (da) * 1999-11-16 2009-08-31 Oncozyme Pharma Inc Pentamidin til behandling af cancer
US20030232394A1 (en) * 2002-06-12 2003-12-18 Aventis Pharma Deutschland Gmbh High throughput screening method and assay system for determining the interaction between C-reactive protein and components binding to it
DE10226011A1 (de) * 2002-06-12 2004-01-08 Aventis Pharma Deutschland Gmbh HTS-fähiges Verfahren und Testsystem zur Ermittlung der Wechselwirkung zwischen c-reaktivem Protein und an C-reaktives Protein bindenden Komponenten
ITMI20022307A1 (it) * 2002-10-30 2004-04-30 Zetesis Spa Associazioni anti-tumorali comprendenti proteine e chemioterapici.
SG10201503351RA (en) 2010-01-19 2015-06-29 Harvard College Engineered Opsonin for Pathogen Detection and Treatment
AU2012284097B2 (en) 2011-07-18 2017-08-03 President And Fellows Of Harvard College Engineered microbe-targeting molecules and uses thereof
JP5713306B2 (ja) * 2013-01-30 2015-05-07 国立大学法人秋田大学 ガンのリンパ節転移抑制剤
WO2014144325A1 (en) 2013-03-15 2014-09-18 President And Fellows Of Harvard College Methods and compositions for improving detection and/or capture of a target entity
JP6649250B2 (ja) 2013-05-21 2020-02-19 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 操作されたヘム結合性構成物およびその使用
US10513546B2 (en) 2013-12-18 2019-12-24 President And Fellows Of Harvard College CRP capture/detection of gram positive bacteria
EP3020726A1 (de) * 2014-11-12 2016-05-18 Pentracor GmbH Verwendung einer Citrat-Lösung zur affinitätschromatographischen Aufreinigung von CRP mittels Phosphocholin und dessen Derivaten
EP3331549B1 (de) 2015-08-06 2020-12-23 President and Fellows of Harvard College Verbesserte mikrobenbindende moleküle und verwendungen davon
TWI887021B (zh) 2020-03-17 2025-06-11 日商紀和化學工業股份有限公司 染料組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444744A (en) * 1980-03-03 1984-04-24 Goldenberg Milton David Tumor localization and therapy with labeled antibodies to cell surface antigens
US4816402A (en) * 1986-01-07 1989-03-28 Northwestern University Murine hybridoma and diagnostic antibody produced thereby
US4857314A (en) * 1986-07-18 1989-08-15 Health Research , Inc. C-reactive proteins in treatment of animal and human cancers
DE68925899T2 (de) * 1988-04-04 1996-10-02 Byron E Anderson Bindung von immunkomplexen durch modifizierte formen von c-reaktiven proteinen

Also Published As

Publication number Publication date
CA2132001C (en) 2000-02-15
JPH07505905A (ja) 1995-06-29
US5283238A (en) 1994-02-01
EP0637246B1 (de) 2003-02-12
JP2003267894A (ja) 2003-09-25
EP0637246A1 (de) 1995-02-08
AU668168B2 (en) 1996-04-26
DE69332688T2 (de) 2003-10-16
DE69332688D1 (de) 2003-03-20
EP0637246A4 (de) 1996-03-27
CA2132001A1 (en) 1993-11-11
AU4110993A (en) 1993-11-29
JP3810741B2 (ja) 2006-08-16
WO1993021944A1 (en) 1993-11-11
US5474904A (en) 1995-12-12

Similar Documents

Publication Publication Date Title
ATE232394T1 (de) Verwendung von modifiziertem c-reaktiven protein zur herstellung eines medikaments zur behandlung von krebs
DE69433889D1 (de) Anwendung von 1,2,4-benzotriazinoxiden zur Herstellung eines Arzneimittels zur Behandlung von Tumoren
DE10199020I2 (de) Galanthamin oder dessen Analoge zur Behandlung derAlzheimerschen Krankheit.
DE69433013D1 (de) Zubereitungen und verfahren für die behandlung von krebs und hyperproliferierenden krankheiten
DE69432409D1 (de) Verwendung der NDV zur Herstellung eines Medikaments zur Krebsbehandlung
ATE296839T1 (de) Antikörper zur krebsbehandlung und -diagnose
ATE105482T1 (de) Behandlung von krebs mit somatostatin und mit analogen davon.
DE69328438D1 (de) Eichenrindenextraktverwandte synthetische zubereitungen und verfahren zur verwendung
BR9607894A (pt) Processo para tratar tumores
ATE222769T1 (de) Verabreichung von gm-csf zur behandlung der gehirntumoren und verhütung deren wiederauftretens
ATE145556T1 (de) Verwendung von interleukin-4 zur behandlung der festen tumoren
ATE81984T1 (de) Verwendung von granulozyt-makrophagen-kolonie erregenden faktor zur herstellung eines medikaments zur behandlung von bakterieller krankheiten.
DE68921979D1 (de) Antikörper für die antilymphozyten-antikörpertherapie.
NO994330L (no) Metode for behandling av en tumor
KR930700163A (ko) 연조직 종양의 치료 및/또는 진단 방법
ATE291918T1 (de) Kombinationstherapie zur behandlung von tumoren
ATE87203T1 (de) Alpha-carotin zur wachstumshemmung von krebszellen.
DE69814691D1 (de) Verwendung von fc101 als hemmstoff der angiogenese zur behandlung von krebs und anderen angiogenen krankheiten
KR890017363A (ko) 스트로빌루린 유도체, 이들의 제법 및 용도
ATE87314T1 (de) Platin-arzneimittel.
DE69117974D1 (de) Pharmazeutische zusammensetzungen zur behandlung von b-zell-entartungen
ATE335494T1 (de) Verwendung von n-glycolneuraminsäure und deren derivaten zur herstellung eines medikaments zur behandlung von hiv-infektionen
SU1098226A1 (ru) Дигидробромид 2-диэтиламиноэтил- n -аллил- n, n' - диэтилизотиурония, обладающий свойствами повышения устойчивости периферического отдела слухового анализатора к воздействию звуковой нагрузки и ототоксическому действию аминогликозидов
RU94026088A (ru) Способ лечения шока и способ ингибирования продуцирования альфа фактора некроза опухоли
RU94033096A (ru) Соединение, способ лечения и фармацевтическая композиция

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties